New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:46 EDTKPTIKaryopharm announces initiation of Selinexor Phase 2 study
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for KPTI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use